Cardiac rhythm management company ELA Medical (Monrouge, France) last month reported the European release of Symphony AAIsafeR 2, its second-generation pacemaker that minimizes ventricular pacing. The company said the AAIsafeR 2 pacing mode is intended to promote the patient’s intrinsic electrical conduction by “drastically limiting” the amo- unt of “unnecessary, often deleterious pacing delivered to the right ventricle.”